美罗华
髓鞘少突胶质细胞糖蛋白
医学
疾病
抗体
髓鞘相关糖蛋白
免疫学
髓鞘
皮肤病科
病理
内科学
中枢神经系统
实验性自身免疫性脑脊髓炎
作者
Philippe‐Antoine Bilodeau,Takahisa Mikami,Anastasia Vishnevetsky,Monique Anderson,Mattia Wruble,Rebecca L. Gillani,Gabriela Romanow,Rebecca Salky,Melanie Delgado,Michael Levy
出处
期刊:Neurology
[Lippincott Williams & Wilkins]
日期:2024-10-08
卷期号:103 (7_Supplement_1)
被引量:2
标识
DOI:10.1212/01.wnl.0001051732.71906.95
摘要
Objective To determine relapse-free survival probabilities in MOGAD patients on rituximab, compare these to inebilizumab, and determine predictors of rituximab failure Background Rituximab efficacy in myelin oligodendrocyte glycoprotein Antibody Disease (MOGAD) relapse prevention is controversial, with some groups finding moderate success, while our group has found significantly lower efficacy compared to IVIG. Design/Methods We performed a retrospective analysis of MOGAD patients at Mass General Brigham. We conducted a Kaplan-Meier survival analysis for patients treated with rituximab and extracted relapse freedom probabilities at 6, 12, 18, 24, and 30 months. We determined survival probabilities from the Kaplan-Meier curves of MOG-IgG positive patients in the inebilizumab NMO-mentum trial. We then performed a multivariate Cox proportional hazards analysis to determine predictors of rituximab failure. Results 201 patients with MOGAD were identified. 56 patients received at least one course of rituximab. Mean age of disease onset was 39.6 years (SD 16.0), and 58.9% were female. 62.5% of patients had never received any prior treatment before starting rituximab. Relapse-free survival probabilities were 60.7% at 6 months, 51.1% at 12 months, and 41.8% at 18 months. The N-MOmentum trial for inebilizumab included 7 MOG IgG positive patients. Only 1/7 patients had a relapse at the end of the open label extension. Using the 18-month relapse probabilities from rituximab-treated MOGAD patients, the probability of observing 1 relapse over this time course is 4.5%, assuming similar efficacy. In a multivariate Cox model, patients who never smoked had a lower risk of failure (HR 0.06, 95% CI 0.00012-0.31), while a one-unit increase in BMI was associated with a higher risk of failure (HR 1.36, 95% CI 1.03-1.79). Conclusions The rituximab failure rate is significant in our cohort, in contrast to the relative efficacy of inebilizumab. This may reflect differences in accessing pathogenic B cells or inebilizumab-mediated depletion of plasmablasts and short-lived plasma cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI